Download PDFPDF

Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case–control study
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Re:Are DPP-4 inhibitors free from risk of hospitalization for heart failure?
    • Carlo B Giorda, Director Diabetes Unit
    • Other Contributors:
      • Roberta Picariello, Barbara Tartaglino, Lisa Marafetti, Fabiana Di Noi, Annalisa Alessiato, Giuseppe Costa, and Roberto Gnavi

    Having carefully read the letter by Donzelli et al., we would like to thank the writers for the comments. It is our intention to stick strictly to the results of our analysis and not to address topics such as glycemic targets and benefit of vegetarian diet in type 2 diabetes which have nothing to do with our paper. By using a validated epidemiological methodology in a real life population, our analysis aimed to see whe...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Are DPP-4 inhibitors free from risk of hospitalization for heart failure?
    • Alberto Donzelli, Director Area of Education for Appropriateness and Evidence Based Medicine
    • Other Contributors:
      • Alessandro Battaggia, Ilenia De Carlo, Giulio Mariani

    The case-control study [1] on administrative data did not find increased risk of hospitalization for heart failure (HF) associated with the use of DPP-4 inhibitors (DPP-4is), versus any other antidiabetic treatment. In DPP-4is users the OR for admission for HF was 1.00 (0.94 to 1.07), with a non-significant 1.01 and 1.02 for incident and recurrent HF, respectively. All-cause mortality was 6% lower in DPP-4i users, whereas...

    Show More
    Conflict of Interest:
    None declared.